Non-invasive imaging of microvascular damage

Journal of Nuclear Cardiology

Volumn 16, Issue 5, 2009, Pages 811-831

  Galiuto, L ^a   Natale, L ^b   Leccisotti, L ^c   Locorotondo, Gabriella ^a   Giordano, A ^c   Bonomo, L ^b   Crea, F ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; AMMONIA N 13; FLUORODEOXYGLUCOSE F 18; MACROSALB TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RUBIDIUM 81; TETROFOSMIN TC 99M; THALLIUM 201; WATER O 15;

ACUTE HEART INFARCTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSTIC IMAGING; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; MICROANGIOPATHY; MICROEMBOLISM; MICROVASCULARIZATION; MICROVASCULATURE; NO REFLOW PHENOMENON; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNDROME X; TAKOTSUBO CARDIOMYOPATHY;

CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; MICROVESSELS;

EID: 70349816774     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-009-9134-5     Document Type: Review

References (88)

1. Galiuto L, DeMaria AN, Iliceto S. Microvascular damage during myocardial ischemia-reperfusion: Pathophysiology, clinical implications and potential therapeutic approach evaluated by myocardial contrast echocardiography. Ital Heart J 2000;1(2):108-16. Review.
2. Maseri A. Ischemic heart disease. New York: Churchill Livingstone; 1995.
3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-508.
4. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: Which comes first? Circulation 1980;62:945-52.
5. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989;80:1846-61.
6. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983;111:98-111.
7. Galiuto L, DeMaria AN, del Balzo U, May-Newman K, Flaim SF, Wolf PL, et al. Ischemia-reperfusion injury at the microvascular level. Treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000;102:3111-6.
8. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal evolution and functional outcome of no reflow: Sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003;89:731-7.
9. Lanza GA. Cardiac syndrome X: A critical overview and future perspectives. Heart 2007;93:159-66.
10. Maseri A, Crea F, Kaski JC, Crake T. Mechanism of angina pectoris in syndrome X. J Am Coll Cardiol 1991;17:499-506.
11. Berman DS, Kang X, Tamarappoo B, Wolak A, Hayes SW, Nakazato R, et al. Stress thallium-201/rest technetium-99m sequential dual isotope high-speed myocardial perfusion imaging. JACC Cardiovasc Imaging 2009;2:273-82.
12. DePuey EG, Gadiraju R, Clark J, Thompson L, Anstett F, Shwartz SC. Ordered subset expectation maximization and wide beam reconstruction "half-time" gated myocardial perfusion SPECT functional imaging: A comparison to "full-time" filtered backprojection. J Nucl Cardiol 2008;15:547-63.
13. Taki J, Matsunari I. Metabolic imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:S34-48.
14. Di Carli MF, Lipton MJ. Cardiac PET and PET/CT imaging, editors. Springer; 2007.
15. Rahmim A, Zaidi H. PET versus SPECT: Strengths, limitations and challenges. Nucl Med Commun 2008;29:193-207.
16. Lucignani G. Respiratory and cardiac motion correction with 4D PET imaging: Shooting at moving targets. Eur J Nucl Med Mol Imaging 2009;36(2):315-9.
17. Gould K, Pan T, Loghin C, Johnson NP, Guha A, Sdringola S. Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: A definitive analysis of causes, consequences, and corrections. J Nucl Med 2007;48:1112-21.
18. Schelbert HR. Quantification of myocardial blood flow: What is the clinical role? Cardiol Clin 2009;27(2):277-89.
19. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for Clinical Use of Radionuclide Imaging). J Am Coll Cardiol 2003;42(7):1318-33.
20. Gerber BL, Ordoubadi FF, Wijns W, Vanoverschelde JL, Knuuti MJ, Janier M, et al. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: Optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron emission tomography for the detection of myocardial viability. Eur Heart J 2001;22(18):1691-701.
21. Abbott BG, et al. [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia. Nucl Med Commun 2007;28:89-94.
22. Bandettini WP, Arai AE. Advances in clinical applications of cardiovascular magnetic resonance imaging. Heart 2008;94:1485-95.
23. Patel AR, Epstein FH, Kramer CM. Evaluation of the microcirculation: Advances in cardiac magnetic resonance perfusion imaging. J Nucl Cardiol 2008;15:698-708.
24. Gerber BL, Raman SV, Nayak K, Epstein FH, Ferreira P, Axel L, et al. Myocardial first-pass perfusion cardiovascular magnetic resonance: History, theory, and current state of the art. J Cardiovasc Magn Reson 2008;10:18.
25. Kirschbaum SW, Van Geuns RJM. Cardiac magnetic resonance imaging to detect and evaluate ischemic heart disease. Hellenic J Cardiol 2009;50:119-26.
26. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI/potential mechanisms. Circulation 1995;92(5):1117-25.
27. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, et al. Contrast echocardiography: Evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr 2009;10(2):194-212.
28. Agati L, Tonti G, Pedrizzetti G, Magri F, Funaro S, Madonna M, et al. Clinical application of quantitative analysis in real-time MCE. Eur J Echocardiogr 2004;5:S17-23.
29. Muro T, Hozumi T, Watanabe H, Yamagishi H, Yoshiyama M, Takeuchi K, et al. Assessment of myocardial perfusion abnormalities by intravenous myocardial contrast echocardiography with harmonic power Doppler imaging: Comparison with positron emission tomography. Heart 2003;89:145-9.
30. Wein K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97(5):473-83.
31. Grayburn PA. "Product safety" compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol 2008;101(6):892-3.
32. Schofer J, Montz R, Mathey DG. Scintigraphic evidence of the "no-reflow" phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 1985;5:593-8.
33. Kondo M, Nakano A, Saito D, Shimono Y. Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998;32:898-903.
34. Hamada S, Nakamura S, Sugiura T, Murakami T, Fujimoto T, Watanabe J, et al. Early detection of the no-reflow phenomenon in reperfused acute myocardial infarction using technetium-99m tetrofosmin imaging. Eur J Nucl Med 1999;26:208-14.
35. Shimizu Y, Kumita S, Cho K, Toba M, Mizumura S, Tanaka K, et al. Evaluation of no-reflow phenomenon using 201 Tl/123 I-BMIPP dual-isotope myocardial SPECT. J Nippon Med Sch 2006;73:258-64.
36. Akutsu Y, Yamanaka H, Nishimura H, Hamazaki Y, Kaneko K, Kodama Y, et al. Thallium-201 and I-123 beta-methyl iodophenyl-pentadecanoic acid dual isotope single photon emission computed tomography for evaluating reperfusion injury after successful reperfusion therapy. Clin Nucl Med 2009;34:213-5.
37. Olszowska M, Tracz W, Przewłocki T, Kostkiewicz M, Podolec P, Zalewski J, et al. The value of myocardial contrast echocardiography compared with SPECT in detecting myocardial perfusion abnormalities in patients with anterior acute myocardial infarction. Kardiol Pol 2004;60(1):27-38.
38. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008;117:3152-6.
39. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-7.
40. Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: Head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med 2002;29:721-7.
41. Camici P, Araujo L, Spinks T, Lammertsma AA, Jones T, Maseri A. Myocardial glucose utilization in ischaemic heart disease: Preliminary results with F18-fluorodeoxyglucose and positron emission tomography. Eur Heart J 1986;7(Suppl C):19-23.
42. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: Basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32(3):217-38.
43. Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation 1995;92:2072-8.
44. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008;117(1):103-14.
45. Bianco JA, Hammes R, Sebree L, Wilson M. Imaging of acute myocardial infarction and reperfusion. Cardiology 1995;86(3):189-96.
46. Wijns W, et al. Accumulation of polymorphonuclear leukocytes in reperfused ischemic canine myocardium: Relation with tissue viability assessed by fluorine- 18 2-deoxy glucose uptake. J Nucl Med 1988;29:1826-32.
47. Stewart RE, Miller DD, Bowers TR, McCullough PA, Ponto RA, Grines CL, et al. PET perfusion and vasodilator function after angioplasty for acute myocardial infarction. J Nucl Med 1997;38:770-7.
48. Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet NR, Cademartiri F, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006;47:40-4.
49. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72.
50. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
51. Rogers WJ, Kramer CM, Geskin G, et al. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation 1999;99:744-50.
52. Nijveldt R, Hofman MBM, Hirsch A, Beek AM, Umans VAWM, Algra PR, et al. Assessment of microvascular obstruction and prediction of short-term remodeling after acute myocardial infarction: Cardiac MR imaging study. Radiology 2009;250(2):363-70.
53. Cochet AA, Lorgis L, Lalande A, Zeller M, Beer JC, Walker PM, et al. Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction. Eur Radiol 2009 [Epub ahead of print].
54. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima AJC. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-9.
55. Hombach V, Grebe OC, Merkle N, Waldermaier S, Höher M, Kochs M, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005;26:549-57.
56. Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Becker LC, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998;32(6):1756-64.
57. Galiuto L, DeMaria AN, May-Newman K, et al. Evaluation of dynamic changes in microvascular flow during ischemia-reperfusion by myocardial contrast echocardiography. J Am Coll Cardiol 1998;32:1096-101.
58. Agati L, Tonti G, Galiuto L, Di Bello V, Funaro S, Madonna MP, et al. Quantification methods in contrast echocardiography. Eur J Echocardiogr 2005;6:S14-S20.
59. Bolognese L, Carrabba N, Parodi G, Santoro GM. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-6.
60. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the no-reflow phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-8.
61. Galiuto L, Garramone B, Scarà A, Rebuzzi AG, Crea F, La Torre G, et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: Results of the multicenter AMICI study. J Am Coll Cardiol 2008;51(5):552-9.
62. Lombardo A, Rizzello V, Galiuto L, Natale L, Giordano A, Rebuzzi A, et al. Assessment of resting perfusion defects in patients with acute myocardial infarction: Comparison of myocardial contrast echocardiography, combined first-pass/delayed contrast-enhanced magnetic resonance imaging and 99mTC-sestamibi SPECT. Int J Cardiovasc Imaging 2006;22:417-28.
63. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no re-flow: The need for a pathogenetic classification. Heart 2004;90:123-5.
64. Funaro S, La Torre G, Madonna M, Galiuto L, Scarà A, Labbadia A, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: Results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009;30(5):566-75.
65. Cimarelli S, Sauer F, Morel O, Ohlmann P, Constantinesco A, Imperiale A. Transient left ventricular dysfunction syndrome: Patho-physiological bases through nuclear medicine imaging. Int J Cardiol 2009 May 12.
66. Burgdorf C. Regional alterations in myocardial sympathetic innervation in patients with transient left-ventricular apical ballooning (Tako-Tsubo cardiomyopathy). J Nucl Cardiol 2008;15(1):65-72.
67. Yoshida T, Hibino T, Kako N, Murai S, Oguri M, Kato K, et al. A pathophysiologic study of Tako-Tsubo cardiomyopathy with F-18 fluorodeoxyglucose positron emission tomography. Eur Heart J 2007;28(21):2598-604.
68. Ito K, Sugihara H, Katoh S, Azuma A, Nakagawa M. Assessment of Tako-Tsubo (ampulla) cardiomyopathy using 99mTc-tetrofosmin myocardial SPECT-comparison with acute coronary syndrome. Ann Nucl Med 2003;17(2):115-22.
69. Feola M, Chauvie S, Rosso GL, Biggi A, Ribichini F, Bobbio M. Reversible impairment of coronary flow reserve in Tako-Tsubo cardiomyopathy: A myocardial PET study. J Nucl Cardiol 2008;15(6):811-7.
70. De Boeck BWL. Reversible 18-FDG-uptake defects on myocardial PET: Is this myocardial resurrection? Int J Cardiol 2008;21:e175-8.
71. Perrone-Filardi P, Bacharach SL, Dilsizian V, Marin-Neto JA, Maurea S, Arrighi JA, et al. Clinical significance of reduced regional myocardial glucose uptake in regions with normal blood flow in patients with chronic coronary artery disease. J Am Coll Cardiol 1994;23(3):608-16.
72. Ito K, Sugihara H, Kinoshita N, Azuma A, Matsubara H. Assessment of Tako-Tsubo cardiomyopathy (transient left ventricular apical ballooning) using 99mTc-tetrofosmin, 123I-BMIPP, 123I-MIBG and 99mTc-PYP myocardial SPECT. Ann Nucl Med 2005;19(6):435-45.
73. Mongillo M, John AS, Leccisotti L, Pennell DJ, Camici PG. Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart. Eur J Nucl Med Mol Imaging 2007;34(8):1172-7.
74. Sharkey SW. Electrocardiogram mimics of acute ST-segment elevation myocardial infarction: Insights from cardiac magnetic resonance imaging in patients with Tako-Tsubo (stress) cardiomyopathy. J Electrocardiol 2008;41:621-5.
75. Nef HM, Mollmann H, Kostin S, Troidl C, Voss S, Weber M, et al. A. Tako-Tsubo cardiomyopathy: Intraindividual structural analysis in the acute phase and after functional recovery Eur Heart J 2007;28:2456-2464.
76. Steen H, Merten C, Katus HA, Giannitsis E. A rare form of midventricular Tako-Tsubo after emotional stress followed up with magnetic resonance imaging. Circulation 2006;114:e248.
77. Galassi AR, Kaski JC, Crea F, Pupita G, Gavrielides S, Tousoulis D, et al. Heart rate response during exercise testing and ambulatory ECG monitoring in patients with syndrome X. Am Heart J 1991;122:458-63.
78. Camici PG, Marraccini P, Gistri R, Salvadori PA, Sorace O, L'Abbate A. Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther 1994;8:221-6.
79. Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 1997;96(3):821-6.
80. Di Monaco A, Bruno I, Sestito A, Lamendola P, Barone L, Bagnato A, et al. Cardiac adrenergic nerve function and microvascular dysfunction in patients with cardiac Syndrome X. Heart 2009;95:550-4.
81. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995;26:1594-9.
82. Rosen SD, Uren NG, Kaski JC, Tousoulis D, Davies GJ, Camici PG. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994;90:50-60.
83. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994;330(25):1782-8.
84. Camici PG. Coronary microvascular dysfunction. N Engl J Med 2007;356(8):830-40.
85. Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002;346(25):1948-53.
86. Vermeltfoort IA, Bondarenko O, Raijmakers PG, Odekerken DA, Kuijper AF, Zwijnenburg A, et al. Is subendocardial ischaemia present in patients with chest pain and normal coronary angiograms? A cardiovascular MR study. Eur Heart J 2007;28(13):1554-8.
87. Lanza GA, Buffon A, Sestito A, Natale L, Sgueglia GA, Galiuto L, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008;51(4):466-72.
88. Galiuto L, Sestito A, Barchetta S, Sgueglia GA, Infusino F, La Rosa C, et al. Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol 2007;99(10):1378-83.